Friday, 1 June 2012
WARNING TO SHAREHOLDERS
The financial Services Authority has received a number of calls from consumers saying they are being targeted by an American company offering to buy their shares in Mediwatch plc.
The company, Campbell & Stewart Advisory Firm, is contacting people mainly about Mediwatch plc, but the FSA is also aware that they are also calling shareholders in a number of other companies. In this instance it is offering to pay over the odds for Mediwatch plc shares, providing the shareholder pays an upfront fee to secure the deal and the FSA are concerned it is a scam.
Jonathan Phelan, the FSA’s head of unauthorised business, said; “We have had reports that a US company called Campbell & Stewart Advisory Firm (www.campbellstewaratadvisory.com) is trying to buy the shares of people who have invested in Mediwatch plc, providing the customer pays an up-front fee first. We strongly believe this is a scam and anybody that is approached by this firm, or any other firm with a similar offer, should be very wary indeed. Calls out of the blue that promise a fantastic return on investment are one of the hallmarks of a scan.
“We have been told that Campbell & Stewart Advisory Firm is telling shareholders that they will pay over the odds for Mediwatch shares as they wish to mount a takeover bid for the company – in fact this is just a ploy to steal your money. Anybody giving money to these firms stands a very real chance of losing it all. If you get a call like this and you’re not sure what to do, please look at the warnings on our website or call us so we can talk you through your options.”
More information on scams and tips on how to avoid them can be found on the FSA website at www.fsa.gov.uk/scams
The FSA regularly updates a list of firms it believes consumers should beware of on its website: www.fsa.gov.uk/warnings. Campbell & Stewart Advisory Firm was added to this list today.
If you receive any unsolicited investment advice:
• Make sure you get the correct name of the person and organisation
• Check that they are properly authorised by the FSA before getting involved. You can check at www.fsa.gov.uk/Pages/register/index.shtml.
• The FSA also maintains on its website a list of unauthorised overseas firms who are targeting, or have targeted, UK investor and any approach from such organisations should be reported to the FSA so that this list can be kept up to date and any other appropriate action can be considered. If you deal with an unauthorised firm, you would not be eligible to receive payment under the Financial Services Compensation Scheme. The FSA can be contacted by completing an online form at www.fsa.gov.uk/pages/doing/regulated/law/alerts/overseas.shtml.
• Inform our Registrar's Compliance Department on
+44 (0) 1252 821390
Details of any share dealing facilities that the company endorses will be included in company mailings.
More detailed information on this or similar activity can be found on the FSA website www.moneymadeclear.fsa.gov.uk/
.
The company, Campbell & Stewart Advisory Firm, is contacting people mainly about Mediwatch plc, but the FSA is also aware that they are also calling shareholders in a number of other companies. In this instance it is offering to pay over the odds for Mediwatch plc shares, providing the shareholder pays an upfront fee to secure the deal and the FSA are concerned it is a scam.
Jonathan Phelan, the FSA’s head of unauthorised business, said; “We have had reports that a US company called Campbell & Stewart Advisory Firm (www.campbellstewaratadvisory.com) is trying to buy the shares of people who have invested in Mediwatch plc, providing the customer pays an up-front fee first. We strongly believe this is a scam and anybody that is approached by this firm, or any other firm with a similar offer, should be very wary indeed. Calls out of the blue that promise a fantastic return on investment are one of the hallmarks of a scan.
“We have been told that Campbell & Stewart Advisory Firm is telling shareholders that they will pay over the odds for Mediwatch shares as they wish to mount a takeover bid for the company – in fact this is just a ploy to steal your money. Anybody giving money to these firms stands a very real chance of losing it all. If you get a call like this and you’re not sure what to do, please look at the warnings on our website or call us so we can talk you through your options.”
More information on scams and tips on how to avoid them can be found on the FSA website at www.fsa.gov.uk/scams
The FSA regularly updates a list of firms it believes consumers should beware of on its website: www.fsa.gov.uk/warnings. Campbell & Stewart Advisory Firm was added to this list today.
If you receive any unsolicited investment advice:
• Make sure you get the correct name of the person and organisation
• Check that they are properly authorised by the FSA before getting involved. You can check at www.fsa.gov.uk/Pages/register/index.shtml.
• The FSA also maintains on its website a list of unauthorised overseas firms who are targeting, or have targeted, UK investor and any approach from such organisations should be reported to the FSA so that this list can be kept up to date and any other appropriate action can be considered. If you deal with an unauthorised firm, you would not be eligible to receive payment under the Financial Services Compensation Scheme. The FSA can be contacted by completing an online form at www.fsa.gov.uk/pages/doing/regulated/law/alerts/overseas.shtml.
• Inform our Registrar's Compliance Department on
+44 (0) 1252 821390
Details of any share dealing facilities that the company endorses will be included in company mailings.
More detailed information on this or similar activity can be found on the FSA website www.moneymadeclear.fsa.gov.uk/
.
LATEST NEWS AND FUTURE EVENTS
Latest News/Website Updates
Urology Times-May 2012 AUA Special Edition
Renal And Urology News-June 2012 EditionMediwatch Positions/Jobs
Mediwatch/Distributor Training Courses
Germany
These courses are via Mediwatch distributor Promedia but not sure if Mediwatch products are being used as part of the training.
10/02/2012 Urogynecology Basic Course (2 days)
02/11/2012 Urogynecology Basic Course (2 days)
08/01/2012 Urogynecology Advanced Course (2 days)
01/09/2012 Urogynecology Advanced Course (2 days)
Basic and Advanced Courses
USA
Three new workshops announced for 2012:
Urodynamics Workshop WPB Date 11,12 Feb 2012 Deadline 27 Jan
ARM Workshop Boston Date 13th Apr 2012 Deadline 23rd Mar
Urodynamics Workshop WPB Date 13,14 Oct 2012 Deadline 28 Sep
Workshops
Future Events Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later
Newsletters
April 2012
Dec 2011
July 2010
January 2010
STUFF THAT MAYBE DID BUT NOW DOESN'T FIT IN WITH THE TITLE...
Mediwatch-Supply Agreement with NHS
Staffordshire University Honorary Doctors 2011-Philip Stimpson-July 2011
Directors' Shareholdings-Issued 28th July
Interim Results for the six months to 30 April 2011-This copy 28th July (RNS-26th July)
Mediwatch-Annual Report-Issued 24th March 2011
Mediwatch-Final Results for year ended 31 October 2010-Issued 27th January 2011
Mediwatch USA Inc. Awarded US General Service Administration Federal Supply Schedule Contract 14th December
OEM Partnership with ACON Laboratories 1st November
Website Update (Aug)-Mobile Watch
Interim Results
Mediwatch Newsletter-July 2010 Edition
OEM Partnership with Thought Technology Ltd Mediwatch-14th June
Germany
These courses are via Mediwatch distributor Promedia but not sure if Mediwatch products are being used as part of the training.
10/02/2012 Urogynecology Basic Course (2 days)
02/11/2012 Urogynecology Basic Course (2 days)
08/01/2012 Urogynecology Advanced Course (2 days)
01/09/2012 Urogynecology Advanced Course (2 days)
Basic and Advanced Courses
USA
Three new workshops announced for 2012:
Urodynamics Workshop WPB Date 11,12 Feb 2012 Deadline 27 Jan
ARM Workshop Boston Date 13th Apr 2012 Deadline 23rd Mar
Urodynamics Workshop WPB Date 13,14 Oct 2012 Deadline 28 Sep
Workshops
Future Events Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later
Newsletters
April 2012
Dec 2011
July 2010
January 2010
STUFF THAT MAYBE DID BUT NOW DOESN'T FIT IN WITH THE TITLE...
Mediwatch-Supply Agreement with NHS
Staffordshire University Honorary Doctors 2011-Philip Stimpson-July 2011
Directors' Shareholdings-Issued 28th July
Interim Results for the six months to 30 April 2011-This copy 28th July (RNS-26th July)
Mediwatch-Annual Report-Issued 24th March 2011
Mediwatch-Final Results for year ended 31 October 2010-Issued 27th January 2011
Mediwatch USA Inc. Awarded US General Service Administration Federal Supply Schedule Contract 14th December
OEM Partnership with ACON Laboratories 1st November
Website Update (Aug)-Mobile Watch
Interim Results
Mediwatch Newsletter-July 2010 Edition
OEM Partnership with Thought Technology Ltd Mediwatch-14th June
Wednesday, 16 May 2012
(England/Wales)Prostate drug abiraterone 'set for NHS use'
General good news for England and Wales:
A drug for advanced prostate cancer
is likely to be approved for NHS use in England and Wales after the medical
watchdog reversed an earlier decision.
Abiraterone, which costs about £3,000 a month and can extend life by more than three months, was initially rejected by NICE for not being cost effective.
The decision prompted an angry response from patients and cancer charities.
Final approval will be made in June after the manufacturer offered the oral tablet at an undisclosed lower price.
'Wonderful news'
Prostate cancer is the most common cancer in men. Once it spreads it cannot be cured - about 10,000 men die every year from the cancer in the UK.
Abiraterone is one of the few treatments available to prolong life in patients with advanced prostate cancer but, in February 2012, NICE (the National Institute for Health and Clinical Excellence) said it was not cost-effective.
The latest draft guidelines by NICE reverse that stance.
Chief executive Sir Andrew Dillon said he was "very pleased" with the decision.
He explained the change of heart: "During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
"This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price; further information on which patients would benefit most and clarification on how many patients could receive the drug."
Janssen said it had gone to "significant lengths" to find a solution, although the scale of the discount has not been made public.
Owen Sharp, the head of the The Prostate Cancer Charity, said: "This announcement represents a resounding triumph for each of the thousands of men with advanced prostate cancer in England and Wales who know just how much the prospect of precious extra time with their loved ones really means.
"We are delighted that NICE has overturned its earlier
decision after reviewing the evidence. We are also pleased that the manufacturer
responded to our call to deliver a further reduction in price.
Cancer Research UK helped in the early stages of development of the drug and gets royalties when it is sold.
Dr Harpal Kumar, the charity's chief executive, said: "This is wonderful news for patients with advanced prostate cancer and, in part, this U-turn is down to the public's disappointment at the initial refusal.
"People's donations have allowed Cancer Research UK to fund the discovery and early development of abiraterone - now they've also helped to ensure prostate cancer patients get access to this important treatment by making their voices heard."
He said the government needed to get "exceptional" drugs to patients sooner and called on the pharmaceutical industry to "price in a realistic way".
'Thrilled'
If NICE approves the drug in June, it will have to be offered by the NHS in England and Wales.
At the moment, NHS patients in England can access the drug through the Cancer Drugs Fund, a pot of money which pays for unapproved cancer drugs.
Earlier this year the Scottish Medicines Consortium said the cost of the drug did not justify the health benefits, but it is still in discussions with the manufactures.
The Welsh government has already made a decision to fund the drug.
Prof Johann de Bono, who led the trials of abiraterone at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, said: "I'm thrilled that this drug will now be routinely available for eligible patients on the NHS.
"Abiraterone acetate is one of only a handful of life-extending drugs for these patients and, importantly, it can also improve quality of life.
"Some of my patients have been taking abiraterone for several years through a clinical trial and are still pain free."
http://www.bbc.co.uk/news/health-18076137
Tuesday, 1 May 2012
LATEST NEWS AND FUTURE EVENTS
Latest News/Website Updates
Urology Times-May 2012 Edition
Urology Times-April 2012 Edition
Renal And Urology News-May 2012 Edition
Renal And Urology News-April 2012 EditionMediwatch Positions/Jobs
Mediwatch/Distributor Training Courses
Germany
These courses are via Mediwatch distributor Promedia but not sure if Mediwatch products are being used as part of the training.
10/02/2012 Urogynecology Basic Course (2 days)
02/11/2012 Urogynecology Basic Course (2 days)
08/01/2012 Urogynecology Advanced Course (2 days)
01/09/2012 Urogynecology Advanced Course (2 days)
Basic and Advanced Courses
USA
Three new workshops announced for 2012:
Urodynamics Workshop WPB Date 11,12 Feb 2012 Deadline 27 Jan
ARM Workshop Boston Date 13th Apr 2012 Deadline 23rd Mar
Urodynamics Workshop WPB Date 13,14 Oct 2012 Deadline 28 Sep
Workshops
Future Events Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later
Mediwatch are exhibiting at this event-Booth 3121
Mediwatch are exhibiting at this event
Newsletters
April 2012
Dec 2011
July 2010
January 2010
STUFF THAT MAYBE DID BUT NOW DOESN'T FIT IN WITH THE TITLE...
Mediwatch-Supply Agreement with NHS
Staffordshire University Honorary Doctors 2011-Philip Stimpson-July 2011
Directors' Shareholdings-Issued 28th July
Interim Results for the six months to 30 April 2011-This copy 28th July (RNS-26th July)
Mediwatch-Annual Report-Issued 24th March 2011
Mediwatch-Final Results for year ended 31 October 2010-Issued 27th January 2011
Mediwatch USA Inc. Awarded US General Service Administration Federal Supply Schedule Contract 14th December
OEM Partnership with ACON Laboratories 1st November
Website Update (Aug)-Mobile Watch
Interim Results
Mediwatch Newsletter-July 2010 Edition
OEM Partnership with Thought Technology Ltd Mediwatch-14th June
Germany
These courses are via Mediwatch distributor Promedia but not sure if Mediwatch products are being used as part of the training.
10/02/2012 Urogynecology Basic Course (2 days)
02/11/2012 Urogynecology Basic Course (2 days)
08/01/2012 Urogynecology Advanced Course (2 days)
01/09/2012 Urogynecology Advanced Course (2 days)
Basic and Advanced Courses
USA
Three new workshops announced for 2012:
Urodynamics Workshop WPB Date 11,12 Feb 2012 Deadline 27 Jan
ARM Workshop Boston Date 13th Apr 2012 Deadline 23rd Mar
Urodynamics Workshop WPB Date 13,14 Oct 2012 Deadline 28 Sep
Workshops
Future Events Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later
Mediwatch are exhibiting at this event-Booth 3121Mediwatch are exhibiting at this eventNewsletters
April 2012
Dec 2011
July 2010
January 2010
STUFF THAT MAYBE DID BUT NOW DOESN'T FIT IN WITH THE TITLE...
Mediwatch-Supply Agreement with NHS
Staffordshire University Honorary Doctors 2011-Philip Stimpson-July 2011
Directors' Shareholdings-Issued 28th July
Interim Results for the six months to 30 April 2011-This copy 28th July (RNS-26th July)
Mediwatch-Annual Report-Issued 24th March 2011
Mediwatch-Final Results for year ended 31 October 2010-Issued 27th January 2011
Mediwatch USA Inc. Awarded US General Service Administration Federal Supply Schedule Contract 14th December
OEM Partnership with ACON Laboratories 1st November
Website Update (Aug)-Mobile Watch
Interim Results
Mediwatch Newsletter-July 2010 Edition
OEM Partnership with Thought Technology Ltd Mediwatch-14th June
Thursday, 19 April 2012
Tuesday, 3 April 2012
LATEST NEWS & FUTURE EVENTS
Latest News/Website Updates
Mediwatch Positions/Jobs
Nurse - part time
Part time qualified nurse required to manage a point of care clinical trial and to provide support to PSA testing events in the community. Full training will be provided. Some evening and weekend work might be required. Car driver with own transport essential - must be eligible to work in the UK.
This vacancy was placed on 06 Apr 2012 by Julie Green
Mediwatch/Distributor Training Courses
Germany
These courses are via Mediwatch distributor Promedia but not sure if Mediwatch products are being used as part of the training.
10/02/2012 Urogynecology Basic Course (2 days)
02/11/2012 Urogynecology Basic Course (2 days)
08/01/2012 Urogynecology Advanced Course (2 days)
01/09/2012 Urogynecology Advanced Course (2 days)
Basic and Advanced Courses
USA
Three new workshops announced for 2012:
Urodynamics Workshop WPB Date 11,12 Feb 2012 Deadline 27 Jan
ARM Workshop Boston Date 13th Apr 2012 Deadline 23rd Mar
Urodynamics Workshop WPB Date 13,14 Oct 2012 Deadline 28 Sep
Workshops
Future Events Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later
Newsletters
Dec 2011
July 2010
January 2010
STUFF THAT MAYBE DID BUT NOW DOESN'T FIT IN WITH THE TITLE...
Mediwatch-Supply Agreement with NHS
Staffordshire University Honorary Doctors 2011-Philip Stimpson-July 2011
Directors' Shareholdings-Issued 28th July
Interim Results for the six months to 30 April 2011-This copy 28th July (RNS-26th July)
Mediwatch-Annual Report-Issued 24th March 2011
Mediwatch-Final Results for year ended 31 October 2010-Issued 27th January 2011
Mediwatch USA Inc. Awarded US General Service Administration Federal Supply Schedule Contract 14th December
OEM Partnership with ACON Laboratories 1st November
Website Update (Aug)-Mobile Watch
Interim Results
Mediwatch Newsletter-July 2010 Edition
OEM Partnership with Thought Technology Ltd Mediwatch-14th June
Mediwatch/Distributor Training Courses
Germany
These courses are via Mediwatch distributor Promedia but not sure if Mediwatch products are being used as part of the training.
10/02/2012 Urogynecology Basic Course (2 days)
02/11/2012 Urogynecology Basic Course (2 days)
08/01/2012 Urogynecology Advanced Course (2 days)
01/09/2012 Urogynecology Advanced Course (2 days)
Basic and Advanced Courses
USA
Three new workshops announced for 2012:
Urodynamics Workshop WPB Date 11,12 Feb 2012 Deadline 27 Jan
ARM Workshop Boston Date 13th Apr 2012 Deadline 23rd Mar
Urodynamics Workshop WPB Date 13,14 Oct 2012 Deadline 28 Sep
Workshops
Future Events Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later
Newsletters
Dec 2011
July 2010
January 2010
STUFF THAT MAYBE DID BUT NOW DOESN'T FIT IN WITH THE TITLE...
Mediwatch-Supply Agreement with NHS
Staffordshire University Honorary Doctors 2011-Philip Stimpson-July 2011
Directors' Shareholdings-Issued 28th July
Interim Results for the six months to 30 April 2011-This copy 28th July (RNS-26th July)
Mediwatch-Annual Report-Issued 24th March 2011
Mediwatch-Final Results for year ended 31 October 2010-Issued 27th January 2011
Mediwatch USA Inc. Awarded US General Service Administration Federal Supply Schedule Contract 14th December
OEM Partnership with ACON Laboratories 1st November
Website Update (Aug)-Mobile Watch
Interim Results
Mediwatch Newsletter-July 2010 Edition
OEM Partnership with Thought Technology Ltd Mediwatch-14th June
Subscribe to:
Posts (Atom)